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Abstract
Background: There is little data regarding use of mineralocorticoid antagonists (MRAs) for patients reduced LV
ejection fraction (LVEF) following acute myocardial infarction (MI). We determined the frequency and temporal
trends of MRA use in these patients.
Methods: We performed a retrospective review of all cases of acute MI between June 1, 2010 and April 1, 2012.
Patients were considered eligible for MRA therapy if they were admitted with acute MI with LVEF ≤ 40 % and had
heart failure symptoms or a history of diabetes.
Results: Of 3910 cases of acute MI, 332 patients were considered eligible for MRA therapy. MRA therapy was prescribed
for 92/332 (28 %) eligible patients, while 66 of 1142 (6 %) of ineligible patients were so treated. Over the study period,
usage in eligible and ineligible patients rose significantly (22 to 30 %, p = 0.08 and 4 to 7 %, p = 0.04 respectively).
Conclusions: Prescription of MRAs for eligible patients occurred in a minority of patients, and demonstrated a modest
increase over time. In patients without an indication for MRAs, a similar trend was observed. Further study is required to
better understand barriers to appropriate use of MRAs in this patient population.
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Background
Pharmacologic interventions such as angiotensin con-
verting enzyme (ACE) inhibitors, angiotensin receptor
antagonists (ARBs) and beta blockers are known to
benefit patients with heart failure (HF) and reduced left
ventricular ejection fraction (LVEF) complicating acute
myocardial infarction (MI). In 2003, following publica-
tion of the Eplerenone Post-Acute Myocardial Infarction
Heart Failure Efficacy and Survival Study (EPHESUS),
mineralocorticoid receptor antagonist (MRA) therapy
was included in this list [1].
The use of MRA therapy in patients with HF and
reduced LVEF is not new. Following the publication of
the Randomized Aldactone Evaluation Study (RALES)
trial, use of spironolactone was considered standard
therapy for patients with moderate to severe HF and
LVEF < 35 % [2]. However, registries have shown a low
uptake in MRA therapy for patients with post-MI and
chronic HF [3, 4]. Following the RALES trial, spironolac-
tone use increased from 3 to only 24 % of patients meet-
ing enrollment criteria [3]. Interestingly, MRA use
increased from 3 to 18 % in patients not meeting RALES
enrollment criteria, with a concurrent increase in hospi-
talizations for hyperkalemia [3, 5].
Evidence for MRA therapy in patients with reduced LVEF
has been accumulating over time. Recent studies such as
Eplerenone in Patients with Systolic Heart Failure and mild
symptoms (EMPHASIS-HF) study showed a significant re-
duction in mortality with the addition of eplerenone to
standard HF therapy in patients with mild to moderate
symptoms and reduced LVEF [6]. Consequently, the
Canadian Cardiovascular Society (CCS) recommended an
MRA be considered for patients already on standard HF
therapy who meet these enrolment criteria [7].
MRAs are thought to be underutilized, and at our
centre we anecdotally noted a low rate of MRA prescrip-
tions for post-MI patients with reduced LVEF. In the
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Canadian Heart Failure network, outpatient MRA ther-
apy utilization approaches 38 % [8]. According to CIHI
data, Calgary area hospitals report a mortality rate below
the national median for MI [9]. This represented an op-
portunity to describe the rate of MRA prescription in a
large cohort of post-MI patients who were presumably
well treated following supportive publications for MRA
use. In addition, temporal changes in prescription of
MRAs could be assessed. We hypothesized that appro-
priate utilization of MRAs would be low with an in-
crease in use over time.
Methods
We completed a retrospective review of patients dis-
charged alive with a diagnosis of acute MI (ICD-10 code
I-21) from three Calgary metropolitan area hospitals be-
tween June 1, 2010 and April 1, 2012. We excluded pa-
tients who underwent hospital transfer and patients who
did not have an assessment of LV function.
From this group of patients we collected the following
clinical information: LVEF, type of MI (ST elevation
(STEMI) or non-ST elevation MI (NSTEMI)), length of
hospitalization, admission blood pressure, admission
heart rate, and admitting service. We obtained past med-
ical history of: HF, previous MI, hypertension, diabetes,
dyslipidemia, and smoking. In addition the following
laboratory information was collected: discharge serum
creatinine, peak potassium and peak troponin. Glomerular
filtration rate (GFR) was estimated using the MDRD
equation [10]. Use of MRA (either spironolactone or
eplerenone), beta-blockers, ACE-inhibitors and ARBs
were assessed based on discharge summaries and elec-
tronic prescription records. LVEF was recorded in order
of preference based on the 2D biplanar Simpson’s model,
subjective estimated LVEF and subjective global
impression.
Patients were considered eligible for MRA therapy if
there was documented LVEF ≤ 40 % and symptoms of
HF or a history of diabetes. Patients were considered in-
eligible if there was documented: allergy or intolerance
to MRA therapy, a serum potassium level > 5.0 meq/L,
estimated GFR <30 mL/min/1.73 m2, or documented pa-
tient refusal. These criteria were based on current ACC
guidelines [11]. A standardized data extraction tool was
used to minimize bias during the data collection
process.
We explored temporal change by comparing pre-
scribing rates of MRAs before (period A) and after
(period B) the date of publication of EMPHASIS-HF
trial (January 6, 2011) for both eligible and ineligible
patients. This date was chosen to investigate the effects
of a landmark trial publication on medication use. All
data were reported using descriptive statistics with
means and standard deviations for continuous variables
and simple percentages for categorical variables. Fisher
exact tests were used to analyze differences in propor-
tions according to categorical stratifications. Linear re-
gression was used to determine a trend in overall use
with the least squares method after dividing usage rates
by quarters, centered around the EMPHASIS-HF publi-
cation date. We performed a logistic regression analysis
using the least squares method to determine factors as-
sociated with MRA prescription, with significance de-
noted by p < 0.05. Analyses were conducted using Stata
version 13 (Stata Corp., College Station, Texas). Ethics
approval was obtained from the University of Calgary
Conjoint Health Research Ethics Board.
Results
We identified 3910 patients discharged alive with a diag-
nosis of acute MI, of whom 1474 had documented re-
duced LVEF. Five hundred ninety-nine patients had
documented LVEF ≤ 40 %, of which 332 met our eligibil-
ity criteria for MRA therapy without exclusions. Patient
characteristics are outlined in Table 1. Study flow sheet
outlining patient inclusion is shown in Fig. 1. Overall, 92
of 332 eligible patients (28 %) were prescribed MRA
therapy. This percentage was numerically lower during
period A (24/108, 22 %) versus those discharged in
period B (68/224 or 30 %, p = 0.07, see Fig. 2), however
this was not statistically significant. If all prescriptions
filled within 6 months of discharge were included,
MRAs were prescribed in 33/108 (31 %) patients for
period A and 79/224 (35 %) for period B (p = 0.23
between periods).
We identified 1142 patients with systolic dysfunction
who did not meet our criteria. In these patients, MRAs
were prescribed in 16/401 (4 %) patients during period
A and 50/741 (7 %) during period B (p = 0.04 between
periods, see Fig. 3).
When considering only patients admitted to a cardiology
service, 32 % were prescribed MRAs, with 16/71 patients
(23 %) given during period A and 54/148 (36 %) for period
B (p = 0.03). For patients not meeting our criteria the corre-
sponding proportions were 14/323 (4 %) and 40/585 (7 %,
p = 0.08). Prescribing rates between periods were not ana-
lyzed for other admitting services due to low patient num-
bers. Cumulative prescribing rates for eligible patients were;
cardiovascular surgery 7/43 (16 %), family practice 7/33
(21 %), and internal medicine 6/18 (33 %). For ineligible pa-
tients, the rates of MRA prescription were: cardiovascular
surgery 4/96 (4 %) family practice 4/58 (7 %) and internal
medicine 3/36 (8 %). There were no significant differences
in prescribing rates between admitting services.
The proportion of eligible patients prescribed MRAs
by quarter are displayed in Fig. 4. However the coeffi-
cient of determination (R2) was only 0.036 (p = 0.02). For
comparison purposes, we also collected the prescription
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rates for other therapies with longstanding indications
for patients with acute MI (see Fig. 1). Beta-blockers
were prescribed at similar rates across periods (99/108,
92 % vs. 211/224, 94 %). There were similar findings for
ACE-inhibitors and ARBs.
We performed a logistic regression analysis to identify
factors associated with MRA prescriptions in both eligible
and ineligible patients. We assessed the following possible
associated factors: age, gender, length of hospitalization, his-
tory of HF, hypertension, diabetes, smoking, dyslipidemia,
and previous MI, systolic blood pressure, heart rate, type of
MI, EF, estimated GFR, peak troponin, and potassium. The
results of this analysis are outlined in Table 2. In patients
eligible for MRA therapy, lower EF, history of smoking, and
history of dyslipidemia were associated with higher rates of
MRA prescription (all p < 0.05). In patients who were
Table 1 Population characteristics for patients with documented systolic dysfunction
Eligible (n = 332) Ineligible (n = 1142)
Demographics Male (%) 250 (75.3 %) 842 (73.7 %)
Age (years) 67.6 +/− 12.8 64.7+/− 13.2
Length of stay (days) 15 +/− 21 9 +/− 13
Medical history Hypertension 199 (59.9 %) 624 (54.6 %)
Dyslipidemia 132 (39.8 %) 407 (35.6 %)
Diabetes 187 (56.3 %) 272 (23.8 %)
Smoking 107 (32.2 %) 399 (34.9 %)
Myocardial infarction 117 (35.2 %) 257 (22.5 %)
Heart failure 86 (25.9 %) 77 (6.7 %)
Clinical data Systolic blood pressure (mmHg) 114 +/−18 119 +/− 23
Heart rate (beats/min) 78 +/− 15 72 +/− 14
Ejection fraction 32.7 +/− 7.1 45.6+/− 6.9
STEMI 141 (42.5 %) 637 (55.8 %)
Laboratory data Peak troponin T (μg/L) 4.0 +/− 5.9 3.7+/− 4.9
Peak potassium (mmol/L) 4.5 +/− 0.4 4.5 +/− 0.5
Estimated GFR (mL/min/1.73 m2) 81 +/− 36 77 +/− 30
EF ejection fraction, μg/L micrograms per liter, μmol/L micromole per liter, mmHg millimeters mercury, mmol/L millimoles per liter, STEMI ST elevation myocardial
infarction. All numerical values shown +/− standard deviation
3910patients
discharge dalive
diagnosis of acute MI
1474 patients with LV dysfunction
599patientswith LVEF40%
332 patients meeting criteria
239 patients without DM or symptoms of HF
28 patients with GFR <30 or elevated potassium
875Patients with LVEF >40%
2346 patients no echo or
normal LV function
Fig. 1 Study flow sheet outlining patient inclusion and exclusion. DM diabetes mellitus, GFR glomerular filtration rate, HF heart failure, LV left
ventricle, LVEF left ventricular ejection fraction
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considered ineligible for MRA therapy, lower EF and his-
tory of HF were associated with higher rates of MRA pre-
scription (all p < 0.05).
Discussion
We had hypothesized that MRA prescription would be
suboptimal in eligible patients with reduced LVEF follow-
ing acute MI. Over time, there was a trend towards an
increase in the utilization of MRA therapy for both eligible
and ineligible patients, although this was not statistically
significant in patients eligible for MRA therapy. Overall,
prescribing rates were significantly lower than we found
for beta-blockers and ACE-inhibitors or ARB’s. For these
agents we found a very high usage rate which did not
change over time, as one might expect of an established
standard of care. We’ve shown that across three medical
centers where overall survival for MI is better than the
norm, there is a low rate of MRA usage [9]. Indeed, this
level is below that seen in other jurisdictions, such as in
Madrid, Spain (50 %), [12] and in many US hospitals [4].
Previous studies have identified suboptimal use of
MRA therapy for patients with HF and reduced LVEF,
but have not, until recently, reported usage rates of
MRAs in post-MI patients with low LVEF [13, 14].
While there has been a clear lack of emphasis on MRA
usage in eligible patients following acute MI, reports re-
garding the usage in chronic HF have hypothesized a
lack of confidence in diagnosis, concerns regarding
medication use in fragile patients, poor awareness of re-
search evidence and individual preference as barriers in
HF management [15, 16]. Additionally, some physicians
may feel that adherence to guidelines does not change
clinical outcomes, which may be true specifically for
MRA therapy [15]. While there was a trend towards an
increase in prescriptions between periods this seemed to
reflect an overall upward trend in usage. This suggests a
role for ongoing educational efforts such as education at
the time of guideline implementation, continuing educa-
tion, and audit-feedback systems [16].
While we did find an increase in appropriate prescrip-
tions over time, we also found a smaller, but statistically
significant increase in use in patients not meeting our
criteria for MRA usage. We identified EMPHASIS-HF
as a landmark trial in MRA therapy that may have
renewed enthusiasm for this class of medications even
though it investigated a different patient population then
our current study [6]. We did see an increase in patients
we deemed ineligible for MRA therapy which may re-
flect a direct impact from this publication or a more glo-
bal trend towards increased use. Interestingly, there
were similar findings following publication of the RALES
trial, suggesting that landmark trials have important ef-
fects outside of their studied populations [3]. Therefore,
it may be of benefit to specifically outline both inclusion
and exclusion criteria in major studies, guidelines and
educational efforts to optimize clinical decision making.
Our study had several important limitations. Due to
the retrospective nature of our study, only data that was
Fig. 2 Prescriptions of MRA, beta-blockers, and ACE-inhibitors or ARBs in
patients meeting criteria for MRA usage between study periods.
MRA mineralocorticoid receptor antagonist, ACE-i angiotensin converting
enzyme inhibitor, ARB angiotensin receptor blocker
Fig. 3 Use of MRAs in patients meeting and not meeting our criteria
between study periods
Fig. 4 Proportion of patients using MRAs by quarter with overall
trend in use
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collected for clinical purposes was recorded. This was a
single-center experience limiting the generalizability of
the results and the small sample size limited our ability
to detect a difference in prescribing rates, particularly
between admitting services. Our exclusion criteria were
more restrictive than would typically be used in clinical
practice. This would have lead to a falsely high usage
rate, making the low use found in our study more sig-
nificant. Finally, in the EPHESUS study, patients were
randomized to eplerenone therapy at an average of
7.3 days [1]. It’s possible that patients were discharged
before MRA therapy could be initiated, however the low
rates of prescriptions in follow-up and lack of impact of
length of hospitalization on utilization argues that this is
not the case.
Conclusions
Despite its limitations, our study highlights some import-
ant considerations. Use of MRAs has increased, but they
continue to be underutilized. Further efforts to improve
the appropriate usage of MRAs are required. Finally, inter-
ventions other than publication of landmark trials are
likely required to accelerate optimal usage of MRAs in eli-
gible patients.
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